查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球化療引起的貧血市場 - 2023-2030年
市場調查報告書
商品編碼
1290353

全球化療引起的貧血市場 - 2023-2030年

Global Chemotherapy-Induced Anemia Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球化療誘導性貧血市場規模在2022年達到22.4億美元，預計到2030年將見證有利可圖的成長，達到38.935億美元。在預測期間（2023-2030年），化療引起的貧血市場預計將呈現7.2%的年成長率。

貧血是一種身體的紅血球狀態低於正常的情況。當身體不包含足夠的紅細胞時，身體各部分不能獲得足夠的氧氣。因此，它們不能以它們需要的方式執行，並誘發問題。如果個人的身體不能產生足夠的紅細胞或將其消除，就會孕育出貧血。因此，如果個人從血液中流失過多的血液，甚至會誘發貧血。貧血是癌症和癌症治療的一個典型副作用，對於接受化療的人來說尤其如此。

市場動態

不斷成長的癌症病例正在推動預測期內的全球化療誘導性貧血市場。

在預測期內，不斷成長的癌症病例正在推動全球化療誘導性貧血市場的發展。例如，根據2022年發表的一項研究報告，在GLOBOCAN 2020中登記的癌症病例估計有1930萬，死亡人數超過1000萬。在這些患者中，全球典型檢測出的癌症的發病率是女性前列腺癌（141萬，7.3%）、肺癌（221萬，11.4%）和乳腺癌（226萬例，11.7%）。

老年人口為全球化療誘發性貧血市場提供了前瞻性的成長機會。

癌症可以在任何年齡段生長，儘管隨著個人年齡的成長，大多數種類的癌症變得更加典型。這是因為身體的細胞會在這段時間內受到傷害。這種惡化會隨著個人年齡的成長而產生，並會經常產生癌症。因此，不斷成長的老年人口為全球市場提供了在未來幾年的成長機會。例如，根據聯合國發布的《2022年世界人口前景》，80歲或以上的人的數量預計將成長三倍，從2022年的1.57億增加到2050年的4.59億。

COVID-19影響分析

COVID-19分析包括COVID前情景、COVID情景和COVID後情景以及定價動態（包括大流行期間和之後的定價變化與COVID前情景的比較）、需求-供應譜（由於貿易限制、封鎖和後續問題造成的需求和供應變化）、政府計劃（政府機構為振興市場、部門或行業採取的計劃）和製造商戰略計劃（這裡將涉及製造商為緩解COVID問題所做的工作）。

俄烏戰爭影響分析

由於烏克蘭的戰爭造成了混亂，使數百萬人背井離鄉，許多烏克蘭人不得不逃到國家的西部地區，成為歐洲和國外的難民。其中有癌症患者，他們遇到了極端疾病和流亡的猛烈一擊。而在烏克蘭的癌症醫院被遺棄甚至被攻擊的同時，烏克蘭的病人在邊界對面，受到製裁和通貨膨脹的打擊，甚至遇到了一個不確定的未來，他們的護理。

全球經濟衰退影響分析

醫療保健行業並非完全不受經濟衰退的影響，因為醫療機構在過去的金融衰退期間認為解僱和就業。儘管如此，由於其基本性質，該行業確實比其他行業應對得更好。然而，隨著通貨膨脹的持續增加，衰退的危險威脅著市場。由於全球已開發國家的高通貨膨脹率，對持續衰退的緊張程度上升，在過去兩年中出現了普遍的成本激增。累積惡化的一般購買控制預計將特別影響成長中的經濟體，並被認為在許多方面有幫助。

目錄

第一章：方法和範圍

  • 研究方法
  • 報告的研究目標和範圍

第二章：定義和概述

第三章：執行摘要

  • 按疾病類型分析
  • 按治療類型簡述
  • 按藥物類型分類
  • 按終端用戶分類
  • 按地區分類

第4章：動態變化

  • 影響因素
    • 驅動因素
      • 研究活動
      • 癌症發病率的成長
    • 限制因素
      • 嚴格的監管機構
    • 機會
    • 政府計劃
    • 影響分析

第五章：行業分析

  • 波特的五力分析
  • 監管分析
  • 價格分析
  • 專利分析
  • PEST分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情況
    • COVID-19期間的情況
    • COVID-19之後的情況
  • 在COVID-19期間的定價動態
  • 需求-供應譜系
  • 大流行期間與市場有關的政府計劃
  • 製造商的戰略計劃
  • 結語

第7章：俄羅斯-烏克蘭戰爭分析

第八章：全球經濟衰退分析

第九章：按疾病類型

  • 輕度貧血
  • 中度貧血
  • 嚴重貧血

第十章：按治療類型分類

  • 紅細胞輸注
  • 紅細胞刺激劑（ESAs）。
  • 鐵劑補充

第十一章：按藥物類型分類

  • 伊波金注射液
  • 普羅克雷特注射液
  • Androxy口服液
  • Aranesp注射液
  • 注射用赤黴素Alfa
  • 其他

第十二章：按終端用戶分類

  • 醫院
  • 專業診所
  • 非住院手術中心
  • 癌症研究中心
  • 癌症康復中心

第13章：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東和非洲

第十四章：競爭格局

  • 競爭格局
  • 市場佔有率分析
  • 合併和收購分析

第十五章：公司簡介

  • Dr. Reddy's Laboratories Ltd.
    • 公司概述
    • 疾病類型組合和描述
    • 財務概況
    • 主要發展情況
  • Pfizer Inc
  • Panacea Biotec Limited
  • SBI PHARMACEUTICALS CO., LTD
  • Tolero Pharmaceuticals, Inc.
  • Vifor Pharma AG
  • Therapure Biopharma Inc.
  • PharmaEssentia Corp.
  • PhytoHealth Corp
  • UBI Pharma Inc

第16章：附錄

簡介目錄
Product Code: PH1420

Market Overview

The Global Chemotherapy-Induced Anemia Market size reached USD 2,240 million in 2022 and is projected to witness lucrative growth by reaching up to USD 3,893.5 million by 2030. The chemotherapy-induced anemia market is expected to exhibit a cagr of 7.2% during the forecast period (2023-2030).

Anemia is a condition in which the body's status of red blood cells goes below normal. When the body does not contain adequate RBCs, the body parts do not acquire sufficient oxygen. As a consequence, they cannot perform in the manner they require to and induce issues. Individuals conceive anemia if their body does not produce adequate RBCs or eliminates them. Thus, individuals can even induce anemia if they lose too much blood from their bloodstream. Anemia is a typical side consequence of cancer and cancer therapy, specifically true for individuals accepting chemotherapy.

Market Dynamics

The Growing Cases Of Cancer Are Driving The Global Chemotherapy-Induced Anemia Market In The Forecast Period.

The growing cases of cancer are driving the global chemotherapy-induced anemia market during the forecast period. For instance, according to a research study published in 2022 worldwide, an assessed 19.3 million cases and over 10 million demises were because of cancer as registered in GLOBOCAN 2020. Among these entire patients, the incidence of typically detected cancers globally were female prostate cancers (1.41 million, 7.3%), lung (2.21 million, 11.4%), and breast (2.26 million cases, 11.7%).

The Geriatric Population Is Providing The Global Chemotherapy-Induced Anemia Market With Prospective Growth Opportunities.

Cancer can grow at any age, despite as individuals get older, a majority of kinds of cancer become more typical. This is because the body's cells can get harmed over the period. This deterioration can then produce up as individual ages, and can frequently yield cancer. Thus, the growing geriatric population presents the global market with prospective growth opportunities in the upcoming years. For instance, according to the World Population Prospects 2022, from the UN, the number of individuals aged 80 or above is anticipated to grow triple fold, from 157 million in 2022 to 459 million by 2050.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine War Impact Analysis

As the warfare in Ukraine released disorder and uprooted millions of individuals, numerous Ukrainians had to escape to the western region of the nation and became refugees in Europe and outside. Among them were individuals with cancer, who encountered a fierce one-two force of extreme sickness and exile. And while cancer hospitals in Ukraine are being deserted or even attacked, Ukrainian patients across the boundary, struck by sanctions and inflation, even encounter an indefinite future for their care.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employment during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession as the high inflation in developed countries worldwide has transpired in a general cost surge over the past two years. The cumulatively deteriorating general purchasing control is anticipated to affect growing economies particularly and is considered helpful in numerous ways.

Segment Analysis

The global chemotherapy-induced anemia market is segmented based on disease type, treatment type, drug type, end-user, and region.

The Erythropoiesis-Stimulating Agents (ESAs) Treatment Type Segment Is Estimated To Hold A 34.1% Share Of The Global Market By 2030.

The erythropoiesis-stimulating agents (ESAs) treatment type segment is estimated to hold about 34% of the total chemotherapy-induced anemia market by 2030, owing to the increasing clinical research activities. For instance, in May 2023, FibroGen, Inc., a top biopharmaceutical enterprise committed to finding, creating, and selling a product line of first-in-class therapeutics, and its associate, FibroGen (China) Medical Technology Development Co., Ltd. informed favorable topline information from corporation's Phase 3 clinical trial of roxadustat for the treatment of anemia in people taking coexisting chemotherapy drug for non-myeloid malignancies in China.

Geographical Analysis

Europe is Estimated To Hold The Second-Largest Share Of The Global Chemotherapy-Induced Anemia Market During The Forecast Period.

Owing to the growing number of cancer deaṭhs and measures to battle against cancer, Europe is estimated to hold about 26.6% of the global chemotherapy-induced anemia market by 2030. For instance, according to the 2022 edition of Health at a Glance, cancer is the second largest basis for death in the European Union following cardiovascular conditions. Over 30-50% of cancer individuals' deaths are avertable, and mortality can also be lowered via premature identification and the essential better punctual, and efficacious cures. Europe's Beating Cancer Plan aims to lower the burden of cancer and handle cancer-related inequalities among and in the governments, with struggles to aid, harmonize and satisfy the activities of Member States.

Competitive Landscape

The major global players in the market include: Dr. Reddy's Laboratories Ltd, Pfizer Inc, Panacea Biotec Limited, SBI PHARMACEUTICALS CO., LTD, Tolero Pharmaceuticals, Inc., Vifor Pharma AG, Therapure Biopharma Inc., PharmaEssentia Corp., PhytoHealth Corp, and UBI Pharma Inc among others.

Why Purchase the Report?

  • To visualize the global chemotherapy-induced anemia market segmentation based on disease type, treatment type, drug type, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of chemotherapy-induced anemia market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global chemotherapy-induced anemia market report would provide approximately 53 tables, 54 figures, and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by Drug Type
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Research Activities
      • 4.1.1.2. Growing Cancer Prevalence
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Authorities
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. PEST Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. By Disease Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.1.2. Market Attractiveness Index, By Disease Type
  • 9.2. Mild Anemia
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Moderate Anemia
  • 9.4. Severe Anemia

10. By Treatment Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.1.2. Market Attractiveness Index, By Treatment Type
  • 10.2. RBC Transfusions
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Erythropoiesis-stimulating agents (ESAs)
  • 10.4. Iron Supplementation

11. By Drug Type

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.1.2. Market Attractiveness Index, By Drug Type
  • 11.2. Epogen Injection
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Procrit Injection
  • 11.4. Androxy Oral
  • 11.5. Aranesp injection
  • 11.6. Epoetin Alfa Injection
  • 11.7. Others

12. By End User

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.1.2. Market Attractiveness Index, By End User
  • 12.2. Hospitals
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Specialty Clinics
  • 12.4. Ambulatory Surgical Centers
  • 12.5. Cancer Research Centers
  • 12.6. Cancer Rehabilitation Centers

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.7.1. The U.S.
      • 13.2.7.2. Canada
      • 13.2.7.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.7.1. Germany
      • 13.3.7.2. The U.K.
      • 13.3.7.3. France
      • 13.3.7.4. Italy
      • 13.3.7.5. Spain
      • 13.3.7.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.7.1. Brazil
      • 13.4.7.2. Argentina
      • 13.4.7.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.7.1. China
      • 13.5.7.2. India
      • 13.5.7.3. Japan
      • 13.5.7.4. Australia
      • 13.5.7.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Dr. Reddy's Laboratories Ltd.
    • 15.1.1. Company Overview
    • 15.1.2. Disease Type Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Pfizer Inc
  • 15.3. Panacea Biotec Limited
  • 15.4. SBI PHARMACEUTICALS CO., LTD
  • 15.5. Tolero Pharmaceuticals, Inc.
  • 15.6. Vifor Pharma AG
  • 15.7. Therapure Biopharma Inc.
  • 15.8. PharmaEssentia Corp.
  • 15.9. PhytoHealth Corp
  • 15.10. UBI Pharma Inc

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us